Multidisciplinary integrated care pathway for von Hippel-Lindau disease.
care pathway
hemangioblastoma
pancreatic neuroendocrine tumor
renal cell carcinoma
retinal angioma
von Hippel-Lindau (VHL)
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
revised:
14
04
2022
received:
08
12
2021
accepted:
22
04
2022
pubmed:
18
5
2022
medline:
12
7
2022
entrez:
17
5
2022
Statut:
ppublish
Résumé
Clinical pathways are care plans established to describe essential steps in the care of patients with a specific clinical problem. They translate (inter)national guidelines into local applicable protocols and clinical practice. The purpose of this article is to establish a multidisciplinary integrated care pathway for specialists and allied health care professionals in caring for individuals with von Hippel-Lindau (VHL) disease. Using a modified Delphi consensus-making process, a multidisciplinary panel from 5 Dutch University Medical Centers produced an integrated care pathway relating to the provision of care for patients with VHL by medical specialists, specialized nurses, and associated health care professionals. Patient representatives cocreated the pathway and contributed quality criteria from the patients' perspective. The panel agreed on recommendations for the optimal quality of care for individuals with a VHL gene mutation. These items were the starting point for the development of a patient care pathway. With international medical guidelines addressing the different VHL-related disorders, this article presents a patient care pathway as a flowchart that can be incorporated into VHL expertise clinics or nonacademic treatment clinics. Medical specialists (internists, urologists, neurosurgeons, ophthalmologists, geneticists, medical oncologists, neurologists, gastroenterologists, pediatricians, and ear-nose-throat specialists) together with specialized nurses play a vital role alongside health care professionals in providing care to people affected by VHL and their families. This article presents a set of consensus recommendations, supported by organ-specific guidelines, for the roles of these practitioners in order to provide optimal VHL care. This care pathway can form the basis for the development of comprehensive, integrated pathways for multiple neoplasia syndromes.
Sections du résumé
BACKGROUND
Clinical pathways are care plans established to describe essential steps in the care of patients with a specific clinical problem. They translate (inter)national guidelines into local applicable protocols and clinical practice. The purpose of this article is to establish a multidisciplinary integrated care pathway for specialists and allied health care professionals in caring for individuals with von Hippel-Lindau (VHL) disease.
METHODS
Using a modified Delphi consensus-making process, a multidisciplinary panel from 5 Dutch University Medical Centers produced an integrated care pathway relating to the provision of care for patients with VHL by medical specialists, specialized nurses, and associated health care professionals. Patient representatives cocreated the pathway and contributed quality criteria from the patients' perspective.
RESULTS
The panel agreed on recommendations for the optimal quality of care for individuals with a VHL gene mutation. These items were the starting point for the development of a patient care pathway. With international medical guidelines addressing the different VHL-related disorders, this article presents a patient care pathway as a flowchart that can be incorporated into VHL expertise clinics or nonacademic treatment clinics.
CONCLUSIONS
Medical specialists (internists, urologists, neurosurgeons, ophthalmologists, geneticists, medical oncologists, neurologists, gastroenterologists, pediatricians, and ear-nose-throat specialists) together with specialized nurses play a vital role alongside health care professionals in providing care to people affected by VHL and their families. This article presents a set of consensus recommendations, supported by organ-specific guidelines, for the roles of these practitioners in order to provide optimal VHL care. This care pathway can form the basis for the development of comprehensive, integrated pathways for multiple neoplasia syndromes.
Identifiants
pubmed: 35579632
doi: 10.1002/cncr.34265
pmc: PMC9542729
doi:
Substances chimiques
Von Hippel-Lindau Tumor Suppressor Protein
EC 2.3.2.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2871-2879Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
J Med Genet. 2017 Jan;54(1):11-18
pubmed: 27539272
Clin Cancer Res. 2017 Jun 15;23(12):e68-e75
pubmed: 28620007
Urol Case Rep. 2019 May 29;27:100922
pubmed: 31687357
World J Urol. 2021 Jul;39(7):2409-2415
pubmed: 32936333
Neth J Med. 2001 Nov;59(5):225-34
pubmed: 11705642
J Neurosurg. 2021 Oct 1;:1-6
pubmed: 34598132
Am J Med Genet A. 2010 Feb;152A(2):327-32
pubmed: 20082463
J Orthop Sports Phys Ther. 2012 Feb;42(2):56-65
pubmed: 22333510
Cancer. 2022 Feb 1;128(3):435-446
pubmed: 34735022
Endocr Relat Cancer. 2013 Dec 20;21(1):63-71
pubmed: 24132471
J Neurol Surg B Skull Base. 2021 Apr 08;83(Suppl 2):e225-e231
pubmed: 35833006
J Med Genet. 1991 Jul;28(7):443-7
pubmed: 1895313
J Med Genet. 1996 Feb;33(2):120-7
pubmed: 8929948
BMJ. 1992 Jul 18;305(6846):160-4
pubmed: 1285753
Psychooncology. 2017 Oct;26(10):1484-1490
pubmed: 27195436
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006632
pubmed: 20238347
Eur J Oncol Nurs. 2006 Dec;10(5):353-63
pubmed: 16807106
Dan Med J. 2013 Dec;60(12):B4763
pubmed: 24355456
BMJ. 1998 Jan 10;316(7125):133-7
pubmed: 9462322
Cancer. 2022 Aug 1;128(15):2871-2879
pubmed: 35579632
Orphanet J Rare Dis. 2013 Feb 25;8:37
pubmed: 23442887
Cancer. 1999 Dec 1;86(11 Suppl):2478-82
pubmed: 10630173
J Mol Diagn. 2019 May;21(3):462-470
pubmed: 30731206
Orphanet J Rare Dis. 2021 Nov 12;16(1):474
pubmed: 34772435
Fam Cancer. 2017 Apr;16(2):271-277
pubmed: 27826806
J Psychosoc Oncol. 2018 Sep-Oct;36(5):624-634
pubmed: 29764331
Nat Med. 2020 Oct;26(10):1508
pubmed: 33029016
Neurology. 2012 Aug 21;79(8):793-6
pubmed: 22875085
J Adv Nurs. 2000 Oct;32(4):1008-15
pubmed: 11095242
J Gen Intern Med. 2009 Nov;24 Suppl 2:S412-6
pubmed: 19838841
Clin Genet. 2010 May;77(5):483-91
pubmed: 20184621
Int J Environ Res Public Health. 2020 Nov 20;17(22):
pubmed: 33233824
Lancet. 1991 May 4;337(8749):1052-4
pubmed: 1673491